Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 4Neoplasm Metastasis 3Lung Neoplasms 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Endometrial Neoplasms 1Cervical Esophagus Adenocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Appendiceal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 3sargramostim 2tislelizumab 1spartalizumab 1milademetan 1devimistat 1dehydroftorafur 1bemarituzumab 1aldesleukin 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Interleukin-2 1IFL protocol 1Hydroxychloroquine 1Gemcitabine 1Fluorouracil 1Cetuximab 1Carboplatin 1Bevacizumab 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × dehydroftorafur × Gynecologic × Clear all
NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2 Recruiting
94 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡